Internal Medicine, Hematology & Oncology · Cleveland, OH
NPI
1366406456
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
9500 Euclid Ave
Cleveland, OH, 44195
Phone (800) 223-2273
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
535 services
Medicare patients, 2024
342
Average age 73
Drug cost, 2024
$3.0M
687 prescriptions
Company payments, 2025
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alan E Lichtin was code 99212 (office e&m - established), 301 times for 181 patients. In total Alan E Lichtin billed 535 services in 16 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-02-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99212 Office E&M - Established | Facility | 301 | 181 | $24.68 | $7,430 |
| 99203 Office E&M - New | Facility | 37 | 37 | $58.76 | $2,174 |
| 99232 Hospital E&M - Subsequent | Facility | 37 | 36 | $58.13 | $2,151 |
| 99213 Office E&M - Established | Facility | 30 | 25 | $38.20 | $1,146 |
| 99204 Office E&M - New | Facility | 27 | 27 | $93.39 | $2,522 |
| 99202 Office E&M - New | Facility | 24 | 24 | $31.42 | $754 |
| 99212 Office E&M - Established | Office | 24 | 19 | $37.55 | $901 |
By year: 2022 $20K for 515 services; 2023 $22K for 556 services; 2024 $21K for 535 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alan E Lichtin prescribed most often to Medicare patients was Hydroxyurea, with 101 prescriptions and refills. In total Alan E Lichtin wrote 687 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 101 | 237 | 25 | $2,409 |
| Prednisone Generic | 61 | 91 | 22 | $306 |
| Eliquis Apixaban | 58 | 79 | 16 | $42K |
| Jakafi Ruxolitinib Phosphate | 37 | 37 | Under 11 | $544K |
| Warfarin Sodium Generic | 31 | 82 | Under 11 | $344 |
| Fabrazyme Agalsidase Beta | 26 | 26 | Under 11 | $473K |
| Xarelto Rivaroxaban | 25 | 46 | Under 11 | $23K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 22 | 22 | Under 11 | $257 |
| Imatinib Mesylate Generic | 15 | 15 | Under 11 | $1,126 |
| Cerdelga Eliglustat Tartrate | 14 | 14 | Under 11 | $411K |
| Anagrelide Hcl Generic | 13 | 38 | Under 11 | $2,154 |
| Acyclovir Generic | 13 | 39 | Under 11 | $354 |
| Givlaari Givosiran Sodium | 13 | 13 | Under 11 | $555K |
| Cephalexin Generic | 12 | 12 | Under 11 | $11.44 |
| Allopurinol Generic | 11 | 29 | Under 11 | $169 |
Brand drugs: - claims; generic drugs: 451 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alan E Lichtin $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.